fradafiban has been researched along with aspirin in 3 studies
*Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5) [MeSH]
*Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5) [MeSH]
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (66.67) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Byrne, A; Crean, P; Fitzgerald, DJ; Maher, M; Moran, N; Walsh, N | 1 |
| Bode, C; Kohler, B; Kübler, W; Moser, M; Nordt, T; Peter, K; Salbach, P; Schwarz, M; Ylänne, J | 1 |
| Byrne, A; Cox, D; Crean, P; Fitzgerald, DJ; Kearney, D | 1 |
2 trial(s) available for fradafiban and aspirin
| Article | Year |
|---|---|
Continued thromboxane A2 formation despite administration of a platelet glycoprotein IIb/IIIa antagonist in patients undergoing coronary angioplasty.
Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Biphenyl Compounds; Bleeding Time; Cell Division; Coronary Disease; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Fibrinogen; Heparin; Humans; Infusions, Intravenous; Male; Middle Aged; Muscle, Smooth, Vascular; P-Selectin; Pilot Projects; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Pyrrolidines; Thrombosis; Thromboxane A2; Thromboxane B2; Vasoconstriction | 1997 |
Optimal suppression of thromboxane A(2) formation by aspirin during percutaneous transluminal coronary angioplasty: no additional effect of a selective cyclooxygenase-2 inhibitor.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Biphenyl Compounds; Cyclooxygenase 1; Cyclooxygenase 2; Dinoprost; Epoprostenol; Female; Humans; Isoenzymes; Male; Membrane Proteins; Middle Aged; Peroxidases; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prostaglandin-Endoperoxide Synthases; Pyrrolidines; Sulfonamides; Thromboxane A2 | 2004 |
1 other study(ies) available for fradafiban and aspirin
| Article | Year |
|---|---|
Induction of fibrinogen binding and platelet aggregation as a potential intrinsic property of various glycoprotein IIb/IIIa (alphaIIbbeta3) inhibitors.
Topics: Abciximab; Animals; Antibodies, Monoclonal; Aspirin; Binding, Competitive; Biphenyl Compounds; CHO Cells; Cricetinae; Disintegrins; Fibrinogen; Humans; Immunoglobulin Fab Fragments; Indomethacin; Mice; Oligopeptides; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Protein Binding; Pyrrolidines; Recombinant Fusion Proteins | 1998 |